Updated:
Accel-Rx Health Sciences Accelerator
Accel-Rx Health Sciences Accelerator is a national organization focused on supporting new health sciences companies in Canada. It merged with adMare...
Accel-Rx Health Sciences Accelerator
Accel-Rx Health Sciences Accelerator is a national organization focused on supporting new health sciences companies in Canada. It merged with adMare BioInnovations on January 9, 2020. Accel-Rx has made 9 investments, including a Series A investment in Inversago Pharma on July 25, 2018.
General information
Firm type
other
Location
Region
North America
Country
Canada
City
Montreal
Corporate office
Montreal, Quebec, Canada
Additional offices
Vancouver · Toronto
Sector focus
Frequently asked questions
What investment stages does Accel-Rx typically target?
Accel-Rx targets pre-seed and seed-stage health science ventures, often at the point of university spinout formation. It provides initial funding of up to CAD 500,000 per company and helps bridge to Series A rounds led by external venture capital firms.
Which sectors does Accel-Rx explicitly avoid?
The accelerator focuses exclusively on health sciences and life sciences. It does not invest in pure software, fintech, or consumer goods. Within health, it emphasizes therapeutics, diagnostics, medical devices, and digital health technologies with a clear path to regulatory approval or clinical adoption.
How is Accel-Rx related to Canadian university research networks?
Accel-Rx is an independent nonprofit that partners with major Canadian research universities and hospital networks. It was established with support from the federal government's Networks of Centres of Excellence program and operates autonomously from any single university. Each hub maintains a formal affiliation with local academic institutions.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: